Pharma BD Deal Intelligence
A $1.2B glucose-monitoring bolt-on that, through a discontinued first-gen CGM and a two-decade R&D detour at the same Alameda site, became the foundation of Abbott's $6.8B/year FreeStyle Libre franchise — one of medtech's great long-tail payoffs, though not a clean or fast one.
Full analysis, sources & comparables →Abbott agrees to acquire TheraSense, taking advantage of a growing US diabetes market; deal expected to close Q2 2004.
FreeStyle Libre, the long-tail product of Abbott's TheraSense buy, has become Abbott's flagship diabetes franchise but now faces rising CGM competition from…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Diabetes blood glucose monitoring; $27/share cash; merged into Abbott Diabetes Care; closed Q2 2004
A $1.2B glucose-monitoring bolt-on that, through a discontinued first-gen CGM and a two-decade R&D detour at the same Alameda site, became the foundation of Abbott's $6.8B/year FreeStyle Libre franchise — one of medtech's great long-tail payoffs, though not a clean or fast one.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / TheraSense Inc. (this deal) | 2004 | $1.2B | 81 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2004 deals · Abbott Laboratories deals